Conference Day One
Wednesday, March 26, 2025
7:30 am Check-In & Coffee
8:20 am Chair’s Opening Remarks
Evaluating Treg Cell Therapy & Treg Modulator Therapies to Uncover the Next Phase of Therapeutic Evolution
8:30 am Industry Leader’s Fireside Chat: Comparing Treg Cell Therapies & Treg Modulators as Effective Treatments for Inflammatory & Autoimmune Diseases
Synopsis
- Exploring the effectiveness of treatment personalization to direct the future of Treg therapies
- Discussing technological challenges in Treg cell therapy, Treg modulator and antigen-specific therapy development
- Comparing Treg cell therapy and modulator treatment efficacy to identify enhancements to progress Treg therapies
9:30 am Keynote Presentation: Alternative Treg Sources: Inducing Immune Tolerance with thyTregs™: A Highly Pure & Stable Treg Population Derived from Thymic Tissue
Synopsis
- Unveiling thyTregs™ as a best-in-class allogeneic Treg therapy platform
- Reviewing thyTreg™ allogeneic product scale-up
- Showcasing the clinical development of a thyTreg™ candidate for tolerance induction and autoimmunities
10:00 am TNFR2 Agonism for Treg Expansion: Why Has the TNF Superfamily Agonism in the Clinic Been So Difficult to Achieve?
Synopsis
- Exploring why agonism to TNF superfamily receptors has been historically difficult to achieve
- Highlighting new structural biology work, suggesting the ADCC mechanism of antibody agonism may not optimize in vivo clinical effects
- Discovering new structural biology data on hexagonal networks stabilized by antibodies, providing a potential new mechanism for improved clinical outcomes
10:30 am Morning Break & Speed Networking
Synopsis
As this community reunites for the seventh time, this session will provide valuable networking time with your peers, enabling you to forge new and lasting connections.
Treg Cell Therapy
Conquering the Transition to the Clinic: Understanding the IND Process & Regulatory Requirements
11:30 am Exploring the Treg Cell Therapy Landscape to Identify Key Trends when Transitioning to the Clinic
Synopsis
- Reviewing the current Treg cell therapy landscape for autoimmune diseases
- Highlighting the key therapy types transitioning to the clinic
- Identifying industry next steps to cultivate, efficient, safe cell therapy development
12:00 pm Panel Discussion: Navigating Regulatory Interactions to Streamline the Approval Process
Synopsis
- Discuss unique company experiences to provide insight into best practices
- Evaluating regulatory setbacks in the drug development process to accelerate successful regulatory approval
- Defining regulatory requirements to optimize treatment development
Treg Modulators
Reimagining Treg Modulation: Exploring Alternatives to IL-2
11:30 am Assessing Novel Therapeutically Active Anti-TNFR2 Agonistic Antibodies in Promoting Treg Proliferation and the Induction of Treg Functional Markers
Synopsis
- Illuminating the unique properties of TNFR2 agonism for Treg targeted therapies
- Optimizing TNFR2 targeting on Tregs with novel approaches
- Showcasing preclinical data from Nektar’s differentiated TNFR2 agonist
12:00 pm Roundtable Discussion: Discussing Alternative Functions of Tregs to Unearth New Perspectives of Disease Treatment
Synopsis
- Exploring the non-immunosuppressive functions of Tregs to accelerate treatment development for inflammatory diseases
- Analyzing mechanistic insights of Treg modulators to evaluate their effectiveness in combating inflammation
- Discussing the use of anti-inflammatory antibodies in combating diseases such as IBD
12:30 pm Lunch Break & Networking
Understanding Allogenic Cell Therapy Biology & Comparing Allogeneic & Autologous Therapies
1:30 pm Unearthing Allogeneic Interactions to Understand their Function In Vivo
Synopsis
- Investigating the functional characteristics of allogenic Tregs to ascertain where they are most effective
- Discovering allogeneic mechanisms of action and immune system and target tissue interactions to identify key differences between the treatments
- Exploring criteria to ensure relevant therapy selection based upon varying disease types, severity and patient immune status
2:00 pm Evaluating Clinical Challenges Associated with Allogeneic Therapies
Synopsis
- Assessing the risks of allogeneic therapies to ensure safe treatment development
- Addressing the persistence of allogeneic therapies without the need for deep lymphodepletion
- Discussing innovations to overcome manufacturing challenges for allogeneic therapies
2:30 pm Panel Discussion: Comparing Allogeneic & Autologous Therapies: Ideal Biology Vs Real-Word Effectiveness
Synopsis
- Comparing the need for treatment availability to treatment rejection risks
- Reviewing therapeutic outcomes associated with both therapeutic options to identify the balance between real-world efficacy and biology
- Highlighting current research and emerging strategies to enhance the success of both therapy types
Reimagining Treg Modulation: Exploring Alternatives to IL-2
1:30 pm Harnessing Peptide-Major Histocompatibility Complex- Based Nanomedicines to Treat Autoimmunity by Expanding Antigen-Specific Tregs In Vivo
Synopsis
- Analyzing nanomedicines as effective triggers of endogenous Treg generation to modulate immunoregulation
- Describing the mechanisms of action involved in the pMHC nanomedicine platform to generate disease specific Tregs
- Exploring applications of pMHC nanomedicines in Liver autoimmunity, T1D and MS
2:00 pm The NanoDisc Platform for Induction of Antigen- Specific Immune Tolerance
Synopsis
- Enabling disease-specific autoimmune therapy by lymph node and tolerogenic organ distribution
- Eliciting tolerizing dendritic cell signaling and bystander suppression
- Discussing applications to disease models
2:30 pm Panel Discussion: Shaping the Future of Treg Modulators to Produce Cutting-Edge Therapies
Synopsis
- Exploring novel Treg modulators beyond IL-2 (including long-acting IL-2 and PD-1 agonists) to uncover new therapeutic capabilities
- Investigating emerging small molecules and biologic modulators to supercharge therapeutic development
- Discovering antibody-specific Treg modulation
3:00 pm Afternoon Break & Poster Session
Synopsis
This is your opportunity to contribute to the conversation and share your cutting-edge
research with this community while discovering exciting work carried out by your peers. To
submit a poster, please contact [email protected].
Leveraging Preclinical Disease Models to Successfully Evaluate Treatment Efficacy & Safety
4:00 pm How to Enhance Predictability of Treg-directed Therapies in Preclinical Models
Synopsis
- Outlining BRGSF-HIS mice: Immunodeficient mice displaying functional human lymphoid and myeloid compartments, without GvHD and side effects
- Evidencing the recruitment of human Treg cells to the site of injury
- Showcasing T-dependent inflammatory diseases modelling in BRGSF-HIS mice
4:30 pm Harnessing In Vivo Disease Models to Turbocharge Treatment Success
Synopsis
- Exploring CAR/TCR/alarmin mediated in vivo targeting for autoimmune and inflammatory diseases
- Illuminating context specific Treg functions including controlling B-cell mediated autoimmunity, tissue repair and tissue protection
- Optimizing murine models to uncover the mechanism of action for Treg cell therapy in autoimmune and inflammatory diseases
- Prioritizing translational relevance of key preclinical biomarkers and endpoints to inform on likelihood of efficacy